Published in Nature on March 31, 2010
Propagation of tau pathology in a model of early Alzheimer's disease. Neuron (2012) 6.23
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol (2013) 3.55
Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28
Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron (2013) 3.09
The many faces of tau. Neuron (2011) 2.89
Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem (2011) 2.86
Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci (2011) 2.60
Chronic traumatic encephalopathy: a potential late effect of sport-related concussive and subconcussive head trauma. Clin Sports Med (2011) 2.60
Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci (2011) 2.47
In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci (2011) 2.00
Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol (2012) 1.89
The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med (2010) 1.86
Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol Neurodegener (2010) 1.68
Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol (2012) 1.64
Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol (2011) 1.62
Rapid cell death is preceded by amyloid plaque-mediated oxidative stress. Proc Natl Acad Sci U S A (2013) 1.61
Degeneration and repair in central nervous system disease. Nat Med (2010) 1.42
Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain (2013) 1.40
Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease. Cell (2012) 1.36
Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain. Am J Pathol (2011) 1.30
The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. J Neurosci (2011) 1.26
Initiation and propagation of neurodegeneration. Nat Med (2010) 1.25
The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement (2013) 1.22
Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proc Natl Acad Sci U S A (2011) 1.21
Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. Acta Neuropathol (2012) 1.21
Mouse models of Alzheimer's disease. Brain Res Bull (2011) 1.19
A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci (2013) 1.17
Loss of fused in sarcoma (FUS) promotes pathological Tau splicing. EMBO Rep (2012) 1.17
Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc Natl Acad Sci U S A (2013) 1.16
A caspase cleaved form of tau is preferentially degraded through the autophagy pathway. J Biol Chem (2010) 1.15
The role of tau kinases in Alzheimer's disease. Curr Opin Drug Discov Devel (2010) 1.15
Tau in physiology and pathology. Nat Rev Neurosci (2015) 1.15
The dendritic hypothesis for Alzheimer's disease pathophysiology. Brain Res Bull (2013) 1.14
Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest (2013) 1.12
Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging. PLoS One (2011) 1.12
CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy. Hum Mol Genet (2011) 1.12
Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model. J Neuropathol Exp Neurol (2011) 1.10
Truncated tau and Aβ cooperatively impair mitochondria in primary neurons. Neurobiol Aging (2011) 1.09
Pseudomonas aeruginosa exotoxin Y is a promiscuous cyclase that increases endothelial tau phosphorylation and permeability. J Biol Chem (2012) 1.08
FLIM FRET technology for drug discovery: automated multiwell-plate high-content analysis, multiplexed readouts and application in situ. Chemphyschem (2011) 1.08
TDP-43-induced death is associated with altered regulation of BIM and Bcl-xL and attenuated by caspase-mediated TDP-43 cleavage. J Biol Chem (2011) 1.08
Frontal cortex neuropathology in dementia pugilistica. J Neurotrauma (2012) 1.08
Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry (2012) 1.07
Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med (2012) 1.06
Spines, plasticity, and cognition in Alzheimer's model mice. Neural Plast (2011) 1.06
Hyperphosphorylation and cleavage at D421 enhance tau secretion. PLoS One (2012) 1.06
Molecular mechanisms of cognitive dysfunction following traumatic brain injury. Front Aging Neurosci (2013) 1.05
The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol (2013) 1.05
Are tangles as toxic as they look? J Mol Neurosci (2011) 1.05
Formation and propagation of tau oligomeric seeds. Front Neurol (2013) 1.04
Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease. Brain Res (2011) 1.04
Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease. Front Neurol (2013) 1.03
In vivo imaging of alpha-synuclein in mouse cortex demonstrates stable expression and differential subcellular compartment mobility. PLoS One (2010) 1.02
Soluble forms of tau are toxic in Alzheimer's disease. Transl Neurosci (2012) 1.02
Blast exposure causes early and persistent aberrant phospho- and cleaved-tau expression in a murine model of mild blast-induced traumatic brain injury. J Alzheimers Dis (2013) 1.02
Mouse models of frontotemporal dementia. Ann Neurol (2012) 1.01
Propagation of tau pathology in Alzheimer's disease: identification of novel therapeutic targets. Alzheimers Res Ther (2013) 1.00
Synaptic alterations in the rTg4510 mouse model of tauopathy. J Comp Neurol (2013) 0.99
Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. PLoS One (2012) 0.97
Reversal of neurofibrillary tangles and tau-associated phenotype in the rTgTauEC model of early Alzheimer's disease. J Neurosci (2013) 0.96
Tangles, Toxicity, and Tau Secretion in AD - New Approaches to a Vexing Problem. Front Neurol (2013) 0.96
Structure and pathology of tau protein in Alzheimer disease. Int J Alzheimers Dis (2012) 0.96
In vivo functional brain mapping in a conditional mouse model of human tauopathy (tauP301L) reveals reduced neural activity in memory formation structures. Mol Neurodegener (2013) 0.95
Depletion of GGA1 and GGA3 mediates postinjury elevation of BACE1. J Neurosci (2012) 0.95
Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine. Biochim Biophys Acta (2011) 0.94
A mitocentric view of Alzheimer's disease suggests multi-faceted treatments. J Alzheimers Dis (2010) 0.93
Caspases in synaptic plasticity. Mol Brain (2012) 0.92
Monitoring protein aggregation and toxicity in Alzheimer's disease mouse models using in vivo imaging. Methods (2010) 0.92
The influence of synaptic activity on neuronal health. Curr Opin Neurobiol (2011) 0.92
Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies. Future Med Chem (2011) 0.92
Zinc-mediated allosteric inhibition of caspase-6. J Biol Chem (2012) 0.92
Ectosomes: a new mechanism for non-exosomal secretion of tau protein. PLoS One (2014) 0.92
Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. Sci Rep (2015) 0.91
Caspase activation without apoptosis: insight into Aβ initiation of neurodegeneration. Nat Neurosci (2011) 0.91
Photoreceptor cell death and rescue in retinal detachment and degenerations. Prog Retin Eye Res (2013) 0.91
Early Alzheimer's and Parkinson's disease pathology in urban children: Friend versus Foe responses--it is time to face the evidence. Biomed Res Int (2013) 0.90
Importance of the caspase cleavage site in amyloid-β protein precursor. J Alzheimers Dis (2010) 0.90
Cdc37/Hsp90 protein complex disruption triggers an autophagic clearance cascade for TDP-43 protein. J Biol Chem (2012) 0.90
Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis. Neuron (2015) 0.89
A shift to organismal stress resistance in programmed cell death mutants. PLoS Genet (2013) 0.89
Interaction between α-synuclein and other proteins in neurodegenerative disorders. ScientificWorldJournal (2011) 0.89
Structural abnormalities in the cortex of the rTg4510 mouse model of tauopathy: a light and electron microscopy study. Brain Struct Funct (2010) 0.89
Alzheimer disease: caspases first. Nat Rev Neurol (2010) 0.89
Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease. J Neurochem (2015) 0.88
Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. EMBO J (2015) 0.88
Extensive p-tau pathology and SDS-stable p-tau oligomers in Alzheimer's cortical synapses. Brain Pathol (2012) 0.88
Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions. Curr Pharm Des (2012) 0.88
NMDA receptors and BAX are essential for Aβ impairment of LTP. Sci Rep (2012) 0.88
A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. J Clin Neurol (2011) 0.87
Hyperphosphorylation-induced tau oligomers. Front Neurol (2013) 0.87
Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice. J Neurosci (2014) 0.86
Tau and caspase 3 as targets for neuroprotection. Int J Alzheimers Dis (2012) 0.86
Stable mutated tau441 transfected SH-SY5Y cells as screening tool for Alzheimer's disease drug candidates. J Mol Neurosci (2012) 0.85
Drosophila spaghetti and doubletime link the circadian clock and light to caspases, apoptosis and tauopathy. PLoS Genet (2015) 0.85
Immunoelectron microscopic and biochemical studies of caspase-cleaved tau in a mouse model of tauopathy. J Neuropathol Exp Neurol (2011) 0.85
Amyloid-β oligomers induce tau-independent disruption of BDNF axonal transport via calcineurin activation in cultured hippocampal neurons. Mol Biol Cell (2013) 0.85
p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice. Neurosci Lett (2014) 0.85
A Peephole into the Brain: Neuropathological Features of Alzheimer's Disease Revealed by in vivo Two-Photon Imaging. Front Psychiatry (2012) 0.84
Neuroinflammation and J2 prostaglandins: linking impairment of the ubiquitin-proteasome pathway and mitochondria to neurodegeneration. Front Mol Neurosci (2015) 0.84
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A (1992) 35.45
Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 8.66
Control of memory formation through regulated expression of a CaMKII transgene. Science (1996) 7.56
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol (1997) 6.02
Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A (2003) 3.85
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem (2003) 3.79
Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol (2002) 3.48
Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci (2005) 3.20
Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest (2004) 2.80
Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet (2009) 2.69
Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol (2006) 2.47
Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease. Am J Pathol (2004) 2.19
X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem (2000) 1.81
The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci (2008) 1.78
In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons. J Neurosci (2008) 1.77
Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol Aging (2004) 1.73
Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease. J Neurosci (2004) 1.48
Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo. J Neurochem (2006) 1.39
Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease. Am J Pathol (2001) 1.35
Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation. J Biol Chem (2006) 1.33
Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy. Am J Pathol (2007) 1.32
AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice. PLoS One (2009) 1.23
Tangle-bearing neurons survive despite disruption of membrane integrity in a mouse model of tauopathy. J Neuropathol Exp Neurol (2009) 1.19
Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease. J Neuropathol Exp Neurol (2008) 1.11
C-terminal truncation modulates both nucleation and extension phases of tau fibrillization. FEBS Lett (2005) 1.09
Caspase-3- and calpain-mediated tau cleavage are differentially prevented by estrogen and testosterone in beta-amyloid-treated hippocampal neurons. Neuroscience (2006) 1.05
Apoptosis in transgenic mice expressing the P301L mutated form of human tau. Mol Med (2008) 1.03
Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB [(trans,trans)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene]. FEBS Lett (2008) 1.00
Truncated tau at D421 is associated with neurodegeneration and tangle formation in the brain of Alzheimer transgenic models. Acta Neuropathol (2009) 0.93
An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage (2006) 25.52
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Live tissue intrinsic emission microscopy using multiphoton-excited native fluorescence and second harmonic generation. Proc Natl Acad Sci U S A (2003) 8.92
Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron (2009) 7.02
Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature (2008) 6.89
Propagation of tau pathology in a model of early Alzheimer's disease. Neuron (2012) 6.23
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science (2007) 5.49
The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex (2008) 5.36
Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci (2005) 4.71
Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol (2002) 4.42
Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2005) 4.34
Family-based association between Alzheimer's disease and variants in UBQLN1. N Engl J Med (2005) 4.34
The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2002) 4.27
Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A (2009) 3.86
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol (2007) 3.83
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Human LilrB2 is a β-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science (2013) 3.59
Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol (2002) 3.48
Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron (2008) 3.46
Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron (2013) 3.43
Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28
Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci (2002) 3.20
Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol (2002) 3.12
Depth-resolved optical imaging and microscopy of vascular compartment dynamics during somatosensory stimulation. Neuroimage (2007) 3.07
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 3.05
Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem (2003) 3.00
Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis (2006) 2.96
Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol (2006) 2.93
Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am J Geriatr Psychiatry (2004) 2.70
Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron (2010) 2.68
Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science (2009) 2.65
Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem (2004) 2.62
Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J Neurosci (2011) 2.53
Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron (2004) 2.53
A systems approach to prion disease. Mol Syst Biol (2009) 2.49
Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol (2006) 2.47
Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology (2013) 2.47
Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci (2010) 2.46
Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci (2002) 2.44
gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science (2009) 2.43
Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One (2008) 2.35
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc Natl Acad Sci U S A (2008) 2.27
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol (2012) 2.20
Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A (2003) 2.13
Structural magnetic resonance imaging in established and prodromal Alzheimer disease: a review. Alzheimer Dis Assoc Disord (2003) 2.12
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem (2005) 2.08
A time domain fluorescence tomography system for small animal imaging. IEEE Trans Med Imaging (2008) 2.05
Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol (2003) 2.05
Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J Neurosci (2004) 1.99
Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci (2009) 1.99
Ultrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer's disease mouse models. PLoS One (2008) 1.95
Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest (2005) 1.94
Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J Neurochem (2004) 1.92
Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med (2004) 1.91
Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J (2010) 1.90
Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Arch Gen Psychiatry (2007) 1.88
Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. Brain (2012) 1.87
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem (2005) 1.85
Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci (2003) 1.85
Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme. J Neurosci (2006) 1.83
Uniform polarity microtubule assemblies imaged in native brain tissue by second-harmonic generation microscopy. Proc Natl Acad Sci U S A (2003) 1.81
Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci (2003) 1.81
A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett (2002) 1.79
TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem (2002) 1.77
In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons. J Neurosci (2008) 1.77
Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A (2006) 1.73
APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis. Exp Neurol (2003) 1.73